Personalized dosing of cancer drug pazopanib tested in early trial

NCT ID NCT01552356

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiveness and side effects by measuring drug levels in the blood. The study also looks at how the body processes the drug and how tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pazopanib hydrochloride (Votrient)
What this could lead to: If successful, this study could help doctors personalize pazopanib dosing to improve effectiveness and reduce side effects for patients with advanced solid tumors.
What could go wrong: This is an early phase I trial with only 54 participants, so results may not apply to all patients. The main goal is safety and dosing, not proving the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID NEOPLASM

Contacts and locations

Locations

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.